Geramizadeh Bita, Ghavvas Roshanak, Kazemi Kurosh, Shamsaeefar Alireza, Nikeghbalian Saman, Malekhosseini Seyed-Ali
Department of Pathology, Shiraz University of Medical Sciences, Shiraz, IR Iran; Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Hepat Mon. 2015 Dec 27;15(12):e33626. doi: 10.5812/hepatmon.33626. eCollection 2015 Dec.
Primary sclerosing cholangitis (PSC) is a chronic disease, characterized by chronic inflammation and fibrosis of bile duct epithelial cells. This is a significant contributory factor to the development of malignancy, most commonly cholangiocarcinoma (CCA), which is the second most common malignant liver tumor.
For the first time in Iran, we intend to describe our experience with cases of PSC, with and without CCA, in explanted livers, and compare our results with those found in other areas of the world.
The study population comprised 181 individuals with a diagnosis of PSC who had undergone liver transplantation in the main liver transplant center of Iran, the largest center of hepatobiliary surgery in the south of that country, over a 3-year period between 2012 and 2014. All explanted livers, with and without CCA, were evaluated.
Of the 181 patients, 16 were found to have CCA, two of whom had been diagnosed after pathologic study of the explanted livers. Therefore it appeared that 8.8% of the patients with PSC in our center had developed CCA before liver transplantation.
A comparison of our results with those obtained from other centers in both Western and Asian countries (which reported CCA in 3.6% - 36.5% of patients with PSC), shows that the incidence of CCA in the patients we studied is intermediate.
原发性硬化性胆管炎（PSC）是一种慢性疾病，其特征为胆管上皮细胞的慢性炎症和纤维化。这是导致恶性肿瘤发生的一个重要因素，最常见的是胆管癌（CCA），它是第二常见的肝脏恶性肿瘤。
在伊朗，我们首次打算描述我们在移植肝脏中对伴有和不伴有CCA的PSC病例的经验，并将我们的结果与世界其他地区的结果进行比较。
研究人群包括181例诊断为PSC的个体，他们在2012年至2014年的3年期间，于伊朗主要的肝移植中心（该国南部最大的肝胆外科中心）接受了肝移植。对所有移植肝脏，无论有无CCA，均进行了评估。
在181例患者中，发现16例患有CCA，其中2例是在对移植肝脏进行病理研究后确诊的。因此，我们中心似乎有8.8%的PSC患者在肝移植前已发生CCA。
将我们的结果与西方和亚洲其他中心（报告PSC患者中CCA发生率为3.6% - 36.5%）的结果进行比较，表明我们研究的患者中CCA的发生率处于中等水平。
